This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub

 

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Matthew James
Clemente
Corporate Vice President of Delivery Systems Engineering, Novo Nordisk A/S,

Matthew Clemente is the Corporate Vice President of Delivery Systems Engineering at Novo Nordisk. He is responsible for the leadership of a portfolio of drug delivery and connected devices.

 

His past roles include Senior Director & Chief Technology Officer at Eli Lilly & Co., Director of Advanced Drug Delivery Systems at Unilife Corp, and various roles of increasing responsibility at multiple Johnson & Johnson companies, primarily in the new product development of insulin pumps at Animas Corp for J&J’s Diabetes Care Franchise.

 

Matthew has a BSc in Biomedical Engineering and an MBA in Finance.